-- Sihuan Pharmaceutical Holdings Group (HKG:0460) said a drug developed by its non wholly-owned subsidiary Xuanzhu Biopharmaceutical (HKG:2575) was found to benefit patients with lung cancer in a late-stage study, according to a Hong Kong bourse filing Monday.
Results from the phase 3 clinical trial showed that dirozalkib demonstrated "statistically and clinically significant efficacy advantages" in the first-line treatment of ALK-positive advanced non-small cell lung cancer.
In the modified intention-to-treat population, the drug was found to have achieved a median progression-free survival of 31.3 months compared with 12.9 months in the control group.
The drug's objective response rate stood at 88.5% with a median duration of response of 32.10 months and a disease control rate of 95.4%.
The firm presented the trial results at the 2026 American Association for Cancer Research annual meeting.